

ORIGINAL RESEARCH

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes



Hananeh Fonoudi, PhD,^{a,b,*} Mariam Jouni, PhD,^{a,b,*} Romina B. Cejas, PhD,^{a,b,†} Tarek Magdy, PhD,^{a,b,†} Malorie Blacard, PhD,^{a,b} Ning Ge, PhD,^{a,b} Disheet A. Shah, PhD,^{a,b} Davi M. Lyra-Leite, PhD,^{a,b} Achal Neupane, PhD,^c Mennat Gharib, BS,^{a,b} Zhengxin Jiang, PhD,^{a,b} Yadav Sapkota, PhD,^c Paul W. Burridge, PhD^{a,b}

ABSTRACT

BACKGROUND Genome-wide association studies and candidate gene association studies have identified more than 180 genetic variants statistically associated with anthracycline-induced cardiotoxicity (AIC). However, the lack of functional validation has hindered the clinical translation of these findings.

OBJECTIVES The aim of this study was to functionally validate all genes associated with AIC using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

METHODS Through a systemic literature search, 80 genes containing variants significantly associated with AIC were identified. Additionally, 3 more genes with potential roles in AIC (*GSTM1*, *CBR1*, and *ERBB2*) were included. Of these, 38 genes exhibited expression in human fetal heart, adult heart, and hiPSC-CMs. Using clustered regularly interspaced short palindromic repeats/Cas9-based genome editing, each of these 38 genes was systematically knocked out in control hiPSC-CMs, and the resulting doxorubicin-induced cardiotoxicity (DIC) phenotype was assessed using hiPSC-CMs. Subsequently, functional assays were conducted for each gene knockout on the basis of hypothesized mechanistic implications in DIC.

RESULTS Knockout of 26 genes increased the susceptibility of hiPSC-CMs to DIC. Notable genes included efflux transporters (*ABCC10*, *ABCC2*, *ABCB4*, *ABCC5*, and *ABCC9*), well-established DIC-associated genes (*CBR1*, *CBR3*, and *RAC2*), and genome-wide association study-discovered genes (*RARG* and *CELF4*). Conversely, knockout of *ATP2B1*, *HNMT*, *POR*, *CYBA*, *WDR4*, and *COL1A2* had no significant effect on the in vitro DIC phenotype of hiPSC-CMs. Furthermore, knockout of the uptake transporters (*SLC28A3*, *SLC22A17*, and *SLC28A1*) demonstrated a protective effect against DIC.

CONCLUSIONS The present findings establish a comprehensive platform for the functional validation of DIC-associated genes, providing insights for future studies in DIC variant associations and potential mechanistic targets for the development of cardioprotective drugs. (J Am Coll Cardiol CardioOnc 2024;6:38-50) © 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

From the ^aDepartment of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; ^bCenter for Pharmacogenomics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; and the ^cDepartment of Epidemiology and Cancer Control, St. Jude Children's Hospital, Memphis, Tennessee, USA. *Drs Fonoudi and Jouni contributed equally to this work. †Drs Cejas and Magdy contributed equally to this work.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received January 11, 2023; revised manuscript received November 16, 2023, accepted November 21, 2023.

Anthracyclines, primarily doxorubicin, constitute a key component in about 60% of cancer treatment regimens,¹ with approximately 35% administered to patients with breast cancer. Despite their efficacy, doxorubicin-induced cardiotoxicity (DIC) occurs in a dose-dependent manner in about 9% of patients, and 98% of these cases emerge within the first year of treatment.² DIC encompasses 4 major interrelated molecular mechanisms: 1) generation of reactive oxygen species (ROS); 2) mitochondrial dysfunction; 3) DNA damage involving TOP2B; and 4) calcium overload leading to sarcomere damage. These mechanisms collectively lead to cardiomyocyte death, clinically determined by troponin detection in peripheral blood and reduced left ventricular ejection fraction.

To date, 5 genome-wide association studies (GWAS)³⁻⁷ and 20 candidate gene association studies⁸ have identified 80 genes with single-nucleotide polymorphisms (SNPs) significantly linked to anthracycline-induced cardiotoxicity (AIC).⁸ Despite this, only 1 AIC-associated variant locus (in *SLC28A3*) has been independently replicated.^{9,10} Thus, the functional validation of AIC-associated variants remains a critical prerequisite before incorporating this information into clinical practice.

The AIC-associated genes can be categorized into 6 major groups on the basis of their hypothesized mechanistic function. 1) Genes associated with ROS production and handling: doxorubicin induces ROS generation predominantly by reduction in the mitochondria, producing semiquinone-producing superoxide (O_2^+) free radicals. 2) Genes related to DNA damage: doxorubicin inflicts DNA damage on cardiomyocytes either by direct intercalation with DNA or by disruption of DNA repair after cleavage by TOP2B. 3) Genes associated with iron uptake: doxorubicin, with a high affinity for iron, can alter iron metabolism through interactions with iron regulatory proteins, stabilizing transferrin transcripts and inhibiting the expression of iron-sequestering proteins.¹¹ 4) Genes associated with transporters controlling doxorubicin uptake and efflux: generally, variants in uptake transporters (ie, members of the solute carrier [SLC] family) are protective against AIC by reducing doxorubicin transport into cardiomyocytes.^{9,10,12,13} Conversely, variants in efflux transporters (adenosine triphosphate-binding cassette [ABC]) are linked to increased intracellular doxorubicin concentration and AIC.¹⁴ 5) Genes involved in calcium handling: doxorubicin directly binds to ryanodine receptors, inducing calcium release from sarcoplasmic reticulum.¹⁵ It also enhances L-type calcium channel activity,¹⁶ leading to

an increased level of intracellular calcium. 6) Genes related to altered electric currents in the cardiomyocytes: after doxorubicin treatment, this can result in impaired contractile function.¹⁷

Previously, we demonstrated that human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) accurately recapitulate patient-specific cardiotoxic responses to doxorubicin.^{13,18,19} In the present study, we functionally validate the role of 38 genes associated with anthracycline cardiotoxicity in patients with cancer using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-based knockout (KO) in hiPSC-CMs, followed by an array of in vitro characterization assays. Our work confirms that 31 genes, identified in GWAS and candidate gene association studies, play mechanistic roles in DIC at the cellular level. This approach provides insights into the impact of each gene KO on DIC development and their potential mechanistic pathways.

METHODS

VARIANT AND GENE CANDIDATE IDENTIFICATION.

Following a comprehensive PubMed search involving both original and review papers investigating genetic risk factors associated with DIC, we compiled a list of potential candidates. These candidates underwent testing for their expression levels in hiPSC-CMs, adult human heart, and fetal human heart¹⁹ (Supplemental Table 1).

HUMAN INDUCED PLURIPOTENT STEM CELL CULTURE, CRISPR/Cas9-MEDIATED KO GENERATION, AND DIFFERENTIATION TO CARDIOMYOCYTES.

For detailed information, refer to the Supplemental Methods. We used a control male hiPSC line with an exogenous *TNNT2* promoter-driven phleomycin D1 resistance cassette for cardiomyocyte purification, as previously described.¹³ All protocols received approval from the Northwestern University Institutional Review Board. Pairs of CRISPR/Cas9 guide RNAs were designed with a separation of >50 bp to induce a large deletion within the earliest common exon of each gene. Supplemental Tables 2 to 4 display all used primers for single guide RNA expression vector generation, a list of potential off-targets, and sequencing primers. We selected 1 KO hiPSC line with the lowest expression of each gene, which was then differentiated into cardiomyocytes and assessed on day 30.

ABBREVIATIONS AND ACRONYMS

ABC	= adenosine triphosphate-binding cassette
AIC	= anthracycline-induced cardiotoxicity
CRISPR	= clustered regularly interspaced short palindromic repeats
DIC	= doxorubicin-induced cardiotoxicity
GWAS	= genome-wide association study/studies
hiPSC-CM	= human induced pluripotent stem cell-derived cardiomyocyte
IC₅₀	= half maximal inhibitory concentration
KO	= knockout
LD₅₀	= median lethal dose
ROS	= reactive oxygen species
SLC	= solute carrier
SNP	= single-nucleotide polymorphism

FIGURE 1 Prioritization of Doxorubicin-Induced Cardiotoxicity-Associated Loci

Rank	Gene	SNP ID	P-value	Odds Ratio	Cardiac Tissue Expression			Reference
					Adult	Fetal	hiPSC-CMs	
1	RARG	rs2229774	5.90E-08	4.7	4	4	4	Aminkeng <i>et al.</i> 2015 ³ - All combined
2	PRDM2	rs7542939	6.50E-07	n.a.	4	4	4	Wells <i>et al.</i> 2017 ⁵ - Combined
3	WDR4	rs15736	2.60E-06	4.4	4	4	4	Aminkeng <i>et al.</i> 2015 ³ - Discovery cohort
4	ZNF521	rs4381672	2.90E-06	4.3	4	4	4	Aminkeng <i>et al.</i> 2015 ³ - Discovery cohort
5	SP4	rs2282889	4.40E-06	0.2	4	4	4	Aminkeng <i>et al.</i> 2015 ³ - Discovery cohort
6	RIN3	rs9323880	6.80E-06	4.2	4	4	4	Aminkeng <i>et al.</i> 2015 ³ - Discovery cohort
7	SLC28A3	rs7853758	1.60E-05	0.36	4	4	4	Visscher <i>et al.</i> 2012+2013 ^{9,10} - Combined
8	ABCC1	rs4148350	2.80E-05	11.86	4	4	4	Visscher <i>et al.</i> 2012 ⁹ - Discovery cohort
9	ABCC9	rs11046217	7.10E-05	4.48	4	4	4	Visscher <i>et al.</i> 2015 ¹² - Discovery cohort
10	ABCC5	rs7627754	1.00E-04	n.a.	4	4	4	Krajinovic <i>et al.</i> 2016 ¹⁴
11	HNMT	rs17583889	3.40E-04	3.67	4	4	4	Visscher <i>et al.</i> 2012 ⁹ - Discovery cohort
12	SLC22A17	rs4982753	4.40E-04	0.5	4	4	4	Visscher <i>et al.</i> 2015 ¹² - Combined
13	GPX3	rs2233302	7.40E-04	0.27	4	4	4	Visscher <i>et al.</i> 2015 ¹² - Discovery cohort
14	SLC28A1	rs2305364	8.10E-04	2.49	4	4	4	Visscher <i>et al.</i> 2012 ⁹ - Replication cohort
15	ERCC2	rs13181	1.00E-03	n.a.	4	4	4	El-Tokhy <i>et al.</i> 2014 ⁶⁰
16	MYH7	rs3743527	1.00E-03	n.a.	4	4	4	Semsei <i>et al.</i> 2012 ⁶²
17	CYP2J2	rs2294950	1.40E-03	3.9	4	4	4	Visscher <i>et al.</i> 2015 ¹² - Combined
18	CBR3	rs1056892	2.00E-03	6.19	4	4	4	Hertz <i>et al.</i> 2016 ⁶²
19	COL1A2	rs42524	2.00E-03	1.79	4	4	4	Visscher <i>et al.</i> 2015 ¹² - Combined
20	SPG7	rs2019604	2.10E-03	0.39	4	4	4	Visscher <i>et al.</i> 2012 ⁹ - Combined
21	HFE	rs1800562	3.00E-03	n.a.	4	4	4	Lipshultz <i>et al.</i> 2013 ⁶³
22	ABCC10	rs1214763	3.10E-03	0.34	4	4	4	Visscher <i>et al.</i> 2015 ¹² - Discovery cohort
23	ABCB4	rs1149222	5.40E-03	1.87	4	4	4	Visscher <i>et al.</i> 2012 ⁹ - Combined
24	GSTP1	rs1695	6.00E-03	9.4	4	4	4	Windsor <i>et al.</i> 2012 ⁶⁴
25	PLCE1	rs932764	6.80E-03	0.36	4	4	4	Hildebrandt <i>et al.</i> 2017 ⁴⁸
26	GSTM1	null	7.00E-03	2.7	4	4	4	Singh <i>et al.</i> 2020 ²⁰
27	CELF4	rs1786814	1.00E-02	22.2	4	4	4	Leger <i>et al.</i> 2016 ⁶⁵
28	CYBA	rs4673	1.00E-02	2	4	4	4	Wojnowski <i>et al.</i> 2005 ⁶⁶
29	HAS3	rs223228	1.00E-02	3.7	4	4	4	Wang <i>et al.</i> 2014 ⁴⁵ - Combined
30	MLH1	rs1800734	1.00E-02	n.a.	4	4	4	Krajinovic <i>et al.</i> 2016 ¹⁴
31	POR	rs13240755	1.38E-02	3.18	4	4	4	Lubieniecka <i>et al.</i> 2013 ⁶⁷
32	RAC2	rs13058338	1.90E-02	1.84	4	4	4	Rossi <i>et al.</i> 2009 ⁴³
33	CAT	rs10836235	2.00E-02	0.284	4	4	4	Rajic <i>et al.</i> 2009 ³⁶
34	NOS3	rs1799983	2.00E-02	n.a.	4	4	4	Krajinovic <i>et al.</i> 2016 ¹⁴
35	ABCC2	rs8187710	2.10E-02	4.3	4	4	4	Aminkeng <i>et al.</i> 2015 ³ - Discovery cohort
36	ATP2B1	rs17249754	4.00E-02	0.07	4	4	4	Hildebrandt <i>et al.</i> 2017 ⁴⁸
37	CBR1	rs9024	3.00E-01	0.45	4	4	4	Hertz <i>et al.</i> 2016 ⁶²
38	ERBB2	rs1058808	3.00E-03	0.09	4	4	4	Boekhout <i>et al.</i> 2016 ⁴⁰

Table showing the 38 doxorubicin-induced cardiotoxicity-associated loci ranked on the basis of the single-nucleotide polymorphism (SNP) with highest *P* value from their respective publications.²³⁻³⁰ The heat map of cardiac tissue expression shows the expression of anthracycline-induced cardiotoxicity-associated genes in adult human heart (*n* = 2), in fetal human heart (*n* = 2), and in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) (*n* = 7) by RNA sequencing. *n* = number of distinct patient-specific samples.


STATISTICAL METHODS. Data are expressed as mean ± SEM. Comparisons were conducted using 1- or 2-way analysis of variance or unpaired 2-tailed Student's *t*-tests, with significant differences defined as *P* < 0.05, *P* < 0.01, *P* < 0.001, and *P* < 0.0001.

For more detailed methods, refer to the [Supplemental Appendix](#).

RESULTS

DIC-ASSOCIATED GENE PRIORITIZATION, KO GENERATION, AND IN VITRO DOXORUBICIN TOXICITY MEASUREMENT. We compiled a table of 429 SNPs associated with DIC, with 180 being unique ([Supplemental Table 1](#)). From

this meta-analysis, we identified 80 SNP-harboring genes significantly linked to AIC. Our bioinformatic analysis did not predict any gain of function resulting from these SNPs. Additionally, we included 3 other potential candidates: *GSTM1*, associated with DIC through deletion rather than a SNP,²⁰ *CBR1*, considered one of the prototypical DIC-associated genes;²¹ and *ERBB2*, implicated in the cardiotoxicity of trastuzumab plus doxorubicin regimens.²² We assessed the expression of 83 genes using RNA sequencing in the fetal heart, adult human heart, and hiPSC-CMs. Subsequently, 38 genes consistently expressed (>10 transcripts per million for hiPSC-CMs) were chosen for KO generation ([Figure 1](#), [Supplemental Table 1](#)).



We generated KO hiPSC-CM lines for each of the 38 genes, with all guide RNA sequences listed in Supplemental Table 2. All KOs were validated using Sanger sequencing (Supplemental Figures 1 to 4, Supplemental Tables 4 and 5). The absence of the knocked-out protein was confirmed using western blot analysis (Supplemental Figures 5 and 6, Supplemental Tables 6 and 7). Additionally, attenuation of the KO gene in the KO lines was further

confirmed using quantitative reverse transcriptase polymerase chain reaction (Figure 2A, Supplemental Table 8). Relevant SNPs contained in the control human induced pluripotent stem cells are detailed in Supplemental Table 9. Of the 38 KOs attempted, KO of 2 genes (*ERCC2* and *ABCC1*) proved incompatible with hiPSC survival, and 1 gene (*SP4*) was incompatible with cardiac differentiation (Supplemental Table 1).

TABLE 1 Mechanistic Implications of Genes Associated With DIC

Group	Gene	First Author (Year) Ref#	Mechanistic Implication
1	<i>CAT</i>	Rajic et al (2009) ³¹	ROS generation/handling ³²
	<i>CBR1</i>	Armenian et al (2013) ³³	ROS generation/handling ³⁴
	<i>CBR3</i>	Visscher et al (2012), ⁹ Armenian (2013) ³³	ROS generation/handling ³⁴
	<i>ERBB2</i>	Boekhout et al (2016) ³⁵	ROS generation/handling ³⁶
	<i>GPX3</i>	Visscher et al (2015) ¹²	ROS generation/handling ³⁷
	<i>GSTM1</i>	Singh et al (2020) ²⁰	ROS generation/handling
	<i>GSTP</i>	Visscher et al (2012), ⁹ Rossi et al (2009) ³⁸	ROS generation/handling ³⁹
	<i>HAS3</i>	Wang et al (2014) ⁴⁰	ROS generation/handling ⁴¹
	<i>NOS3</i>	Krajinovic et al (2016) ¹⁴	ROS generation/handling ⁴²
	<i>PLCE1</i>	Hildebrandt et al (2017) ⁴³	ROS generation/handling ⁴⁴
	<i>RAC2</i>	Armenian et al (2013), ³³ Rossi et al (2009) ³⁸	ROS generation/handling ⁴⁵
	<i>SPG7</i>	Visscher et al (2013) ¹⁰	ROS generation/handling ⁴⁶
2	<i>PRDM2</i>	Wells et al (2017) ⁵	DNA damage ⁴⁷
	<i>MLH1</i>	Krajinovic et al (2016) ¹⁴	DNA damage ⁴⁸
	<i>RARG</i>	Aminkeng et al (2015) ³	DNA damage ³
3	<i>HFE</i>	Armenian et al (2013) ³³	Iron uptake and homeostasis ⁴⁹
4	<i>SLC22A17</i>	Visscher et al (2015) ¹²	DOX uptake ¹³
	<i>SLC28A1</i>	Visscher et al (2012) ⁹	DOX uptake ⁵⁰
	<i>SLC28A3</i>	Visscher et al (2012), ⁹ Visscher et al (2013) ¹⁰	DOX uptake ¹⁹
	<i>ABCB4</i>	Visscher et al (2012) ⁹	DOX efflux ⁵¹
	<i>ABCC2</i>	Aminkeng et al (2015) ³	DOX efflux ⁵²
	<i>ABCC5</i>	Krajinovic et al (2016) ¹⁴	DOX efflux ¹⁴
	<i>ABCC9</i>	Visscher et al (2015) ¹²	DOX efflux ⁵³
	<i>ABCC10</i>	Visscher et al (2015) ¹²	DOX efflux ⁵³
5	<i>CELF4</i>	Wang et al (2016) ⁶	Calcium handling ⁵⁴
	<i>MYH7</i>	Wasielewski et al (2014) ⁵⁵	Calcium handling ⁵⁶
6	<i>CYP2J2</i>	Visscher et al (2015) ¹²	Cardiac electrical activity ⁵⁷
	<i>RIN3</i>	Aminkeng et al (2015) ³	Cardiac electrical activity ⁵⁸
	<i>ZFN521</i>	Aminkeng et al (2015) ³	Cardiac electrical activity ⁵⁹


DIC = doxorubicin-induced cardiotoxicity; DOX = doxorubicin; ROS = reactive oxygen species.

Next, the remaining 35 KO hiPSC lines were differentiated into cardiomyocytes and exposed to 5-log doses of doxorubicin (10^{-8} to 10^{-4} M) for 72 hours, followed by viability assessment to establish the dose required to kill 50% of the cells (median lethal dose [LD₅₀]) (Figure 2B). KO of the uptake drug transporters *SLC28A3*, *SCL22A17*, and *SLC28A1* increased viability after treatments with doxorubicin, with LD₅₀ values between 6.35 and 11.2 μ M compared with 3.78 μ M in isogenic control hiPSC-CMs (Figure 2B, Supplemental Figure 7). KO of *ATP2B1*, *HMNT*, *POR*, *CYBA*, *WDR4*, and *COL1A2* did not alter viability after doxorubicin treatments (Figure 2B, Supplemental Figure 8). KO of the rest of the genes (n = 26) increased the hiPSC-CMs' sensitivity to doxorubicin (Figure 2B, Supplemental Figures 9 and 10). LD₅₀ values for KOs with increased sensitivity to doxorubicin ranged between 0.32 μ M (*NOS3*-KO and *MYH7*-KO cardiomyocytes; $P < 0.0001$) and 2 μ M (*GSTM1*-KO cardiomyocytes; $P = 0.0018$) compared with 3.78 μ M for isogenic control hiPSC-CMs.

FUNCTIONAL VALIDATION OF DIC-ASSOCIATED GENES. Next, for each gene KO, we performed a functional study to investigate their potential mechanistic implications for DIC. We categorized the genes into 6 functional groups (Table 1) and adopted a functional assay relevant to their mechanisms of action (Central Illustration).


Genes involved in ROS production and handling. The largest group of genes in our list (12 of 35) is associated with ROS production and handling (Table 1). We assessed the H₂O₂ levels in hiPSC-CMs after 24 hours of doxorubicin treatment (Figures 3A to 3C). After doxorubicin treatment, our analysis indicated that ROS levels were lower in *CBR1*-KO (half maximal inhibitory concentration [IC₅₀] = 20.6 mM; $P = 0.0024$) and *CBR3*-KO (IC₅₀ = 31 mM; $P = 0.0069$) hiPSC-CMs compared with isogenic control hiPSC-CMs (IC₅₀ = 4.1 mM) (Figure 3A). However, after doxorubicin treatment, ROS levels were increased in *SPG7*-KO (IC₅₀ = 0.3 mM; $P = 0.0006$), *HAS3*-KO (IC₅₀ = 0.1 mM; $P = 0.0023$), *GSTM1*-KO (IC₅₀ = 0.26 mM; $P = 0.039$), and *RAC2*-KO

CENTRAL ILLUSTRATION Mechanistic Implications of Relevant Candidate Genes in DOX-Induced Cardiotoxicity



Fonoudi H, et al. J Am Coll Cardiol CardioOnc. 2024;6(1):38-50.

The different mechanisms of cardiotoxicity after exposure to doxorubicin (DOX) are highlighted in colored boxes. AA = arachidonic acid; ABC = adenosine triphosphate-binding cassette; EET = epoxyeicosatrienoic acid; mRNA = messenger RNA; ROS = reactive oxygen species; SLC = solute carrier; SR = sarcoplasmic reticulum.

FIGURE 3 Reactive Oxygen Species Production, DNA Damage, and Iron Uptake

(A-C) Hydrogen peroxide levels measured by ROS-Glo assay (luminescence) in hiPSC-CMs after doxorubicin treatments (24 hours). (D) Representative images for γH2AX immunofluorescent staining in hiPSC-CMs after treatments with doxorubicin (24 hours, 1 and 3 μM). (E) Quantification of DNA damage on the basis of γH2AX staining in hiPSC-CMs using flow cytometry (ISO, $n = 5$; PRDM2-KO, $n = 5$; and MLH1-KO, $n = 5$). (F) Effect of HFE knockout on hiPSC-CM iron uptake (ISO, $n = 6$; and HFE-KO, $n = 6$) measured using calcein staining. Error bars represent $\pm\text{SEM}$. $n =$ full independent experimental replicates. $^*P < 0.05$, $^{**}P \leq 0.01$, $^{***}P < 0.001$, and $^{****}P < 0.0001$ by Mann-Whitney U test (A-C) and 2-way analysis of variance (E and F). DAPI = 4',6-diamidino-2-phenylindole; IC_{50} = half maximal inhibitory concentration; other abbreviations as in Figure 2.

($\text{IC}_{50} = 0.5 \text{ mM}$; $P = 0.04$) hiPSC-CMs (Figure 3B). No significant differences in ROS production were detected in PLCE1-KO, ERBB2-KO, CAT-KO, GSTP1-KO, NOS3-KO, and GPX3-KO hiPSC-CMs (Figure 3C).

Genes involved in DNA damage. RARG, PRDM2, and MLH1 were linked to DNA damage response^{3,19,47,48,60} (Table 1). Given our comprehensive study of the role of RARG in DIC,¹⁹ we directed our focus to PRDM2 and MLH1 to quantify double-

stranded DNA breaks in hiPSC-CMs after doxorubicin treatment. Our immunofluorescence analysis suggests increased γ H2AX staining in *PRDM2*-KO and *MLH1*-KO compared with isogenic hiPSC-CMs (Figure 3D). The elevated levels of γ H2AX⁺ cells were further confirmed using flow cytometry after 1- and 3- μ M doxorubicin treatments (Figure 3E). *PRDM2* (22.1% \pm 1.88% [$P = 0.0283$] and 32.16% \pm 2.43% [$P = 0.047$]) and *MLH1* (40.07% \pm 5.79% [$P < 0.0001$] and 51.11% \pm 3.2% [$P < 0.0001$]) KOs expressed higher levels of γ H2AX after 1- and 3- μ M doxorubicin treatments compared with isogenic control hiPSC-CMs (12.1% \pm 2.37% and 23.52% \pm 0.98%, respectively).

Genes involved in iron uptake and homeostasis. *HFE* encodes the homeostatic iron regulator protein, which controls iron transport and metabolism. The intracellular iron disposition in cardiomyocytes was examined by measuring iron-calcein quenching. No significant differences in iron uptake were observed in the presence of 0 and 10 μ M Fe²⁺. However, *HFE*-KO hiPSC-CMs exposed to 100 μ M of Fe²⁺ exhibited significantly reduced iron uptake (Figure 3F).

Genes involved in doxorubicin uptake and efflux. Doxorubicin uptake was assessed by measuring intracellular doxorubicin autofluorescence using flow cytometry after drug treatments.¹³ After the 1- μ M doxorubicin treatment, *SLC28A1*-KO cardiomyocytes exhibited significantly reduced doxorubicin uptake (4.6% \pm 2.5%; $P = 0.0039$) compared with isogenic control hiPSC-CMs (18.63% \pm 3.24%) (Figure 4A). Conversely, doxorubicin uptake was significantly higher in *ABCB4*-KO (52.73% \pm 3.2%; $P < 0.0001$), *ABCC5*-KO (48.45% \pm 5.5%; $P < 0.0001$), *ABCC9*-KO (29.98% \pm 2.7%; $P = 0.0327$), and *ABCC10*-KO hiPSC-CMs (60.18% \pm 2.6%; $P < 0.0001$) (Figure 4A). After 1- μ M treatments, no significant differences in doxorubicin uptake were observed in *SLC22A17*-KO, *SLC28A3*-KO, and *ABCC2*-KO hiPSC-CMs (Figure 4A).

Upon increasing the doxorubicin concentration to 3 μ M, all the cells, except for *ABCC10*-KO, exhibited significant differences in doxorubicin uptake compared with control. Doxorubicin uptake was significantly lower in *SLC22A17*-KO (43.55% \pm 3.04%; $P = 0.0005$), *SLC28A1*-KO (35.11% \pm 2.63%; $P < 0.0001$), and *SLC28A3*-KO (35.24% \pm 1.36%; $P < 0.0001$) hiPSC-CMs compared with isogenic control hiPSC-CMs (57.68% \pm 3.11%) (Figure 4A). Conversely, 3- μ M doxorubicin treatment led to significantly higher doxorubicin uptake in *ABCB4*-KO

(71.77% \pm 3.02%; $P = 0.0001$), *ABCC2*-KO (74.52% \pm 1.57%; $P = 0.0003$), *ABCC5*-KO (79.52% \pm 3.79%; $P < 0.0001$), and *ABCC9*-KO (68.57% \pm 1.02%; $P = 0.04$) hiPSC-CMs (Figure 4A).


Genes involved in calcium handling. *CELFL4* and *MYH7* play crucial roles in controlling cardiomyocyte function by affecting calcium transients. KO of *CELFL4* resulted in a significant shortening of full width at half maximum (99.89% \pm 5.67%; $P < 0.0001$), calcium transient duration at 75% (158.04% \pm 8.79%; $P < 0.0001$), and decay time (60.83% \pm 3.5%; $P < 0.0001$) of calcium transients compared with isogenic control hiPSC-CMs (328.15% \pm 17.27%, 449.41% \pm 23.04%, and 172.73% \pm 8.27%, respectively) (Figure 4B). On the contrary, KO of *MYH7* resulted in a significant prolongation in full width at half maximum (441.44% \pm 18.21%; $P < 0.0001$), calcium transient duration at 75% (543.82% \pm 22.4%; $P < 0.0023$), and decay time (262.82% \pm 11.56%; $P < 0.0001$) compared with isogenic control hiPSC-CMs (Figure 4B).

GENE INVOLVED IN CARDIAC ELECTRIC ACTIVITY.

We identified 3 genes, *RIN3*, *ZFN521*, and *CYP2J2*, associated with cardiac electric activity⁵⁷⁻⁵⁹ (Table 1). Impedance measurement revealed that KO of *RIN3* increased the pulse width at 50% (1.41% \pm 0.007% vs 0.89% \pm 0.006%; $P < 0.0001$) and upstroke velocity (331% \pm 3.37% vs 214% \pm 7.02%; $P < 0.0001$) and reduced the relaxation velocity (-166% \pm 2.94% vs -192% \pm 6.74%; $P < 0.0001$), compared with isogenic control hiPSC-CMs (Figure 4B). KO of *ZFN521* resulted in hiPSC-CMs with increased pulse width at 50% (1.17% \pm 0.005%; $P < 0.0001$) and upstroke velocity (141% \pm 1.55%; $P < 0.0001$) and reduced relaxation velocity (-43.2% \pm 0.32%; $P < 0.0001$). KO of *CYP2J2* resulted in increased beat rate (38.39% \pm 3.82% vs 21.7% \pm 0.26%; $P < 0.0004$) and pulse width at 50% (1.03% \pm 0.01%; $P < 0.0001$) and decreased upstroke velocity (15.53% \pm 0.5%; $P < 0.0001$) and relaxation velocity (-13.98% \pm 0.58%; $P < 0.0001$), compared with isogenic control hiPSC-CMs (Figure 4B).

DISCUSSION

Inter-individual cardiotoxic response to doxorubicin is variable, indicating that genetics plays an important role in DIC response. The functional validation of genes and variants associated with cardiotoxicity risk is essential to improve the outcome of anthracycline regimens and to develop cardioprotective treatments.

FIGURE 4 Doxorubicin Uptake, Calcium Handling, and Contractility

(A) Doxorubicin uptake in hiPSC-CMs with knockouts of *SLC* and *ABC* transporters (isotype, $n = 11$; *SLC28A3*-KO, $n = 4$; *SLC22A17*-KO, $n = 6$; *SLC28A1*-KO, $n = 4$; *ABCC2*-KO, $n = 4$; *ABCB4*-KO, $n = 7$; *ABCC5*-KO, $n = 4$; *ABCC9*-KO, $n = 4$; and *ABCC10*-KO, $n = 4$). $n =$ full independent experimental replicates. (B) Effect of knocking out *MYH7* and *CELF4* on calcium transients. Left: representative calcium transients. Middle left: full width at half maximum (FWHM). Middle right: calcium transient duration 75% (CTD_{75}). Right: decay time. (C) Contractility analysis using impedance measurement in *RIN3*-KO, *ZFN521*-KO, and *CYP2J2*-KO hiPSC-CMs (ISO, $n = 41$; *RIN3*-KO, $n = 48$; *ZFN521*-KO, $n = 48$; and *CYP2J2*-KO, $n = 89$). $n =$ number of assessed wells of 96-well plate derived from at least 3 independent rounds of differentiation (B and C). Error bars represent \pm SEM. * $P < 0.05$, ** $P \leq 0.01$, *** $P < 0.001$, and **** $P < 0.0001$ by 2-way analysis of variance (A) and 1-way analysis of variance (B and C). Abbreviations as in Figure 2.

KNOCKING OUT DIC-RELATED GENES ALTERS THE hiPSC-CM RESPONSE TO DOXORUBICIN TREATMENT. Of the 35 genes studied, 3 gene KOs were protective of DIC (*SLC28A3*, *SLC22A17*, and *SLC28A1*), 6 gene KOs did not have a significant effect on DIC (*ATP2B1*, *HNMT*, *POR*, *CYBA*, *WDR4*, and *COL1A2*), and 26 KOs increased DIC (*ABCC10*, *ABCC2*, *ABCB4*, *ABCC5*, *ABCC9*, *CAT*, *CBR1*, *CBR3*, *CYP2J2*, *ERBB2*, *GPX3*, *GSTM1*, *GSTP1*, *HAS3*, *HFE*, *MLH1*, *MYH7*, *NOS3*, *PLCE1*, *PRDM2*, *RAC2*, *RARG*, *RIN3*, *SPG7*, *CELF4*, and *ZFN521*).

ROS PRODUCTION IS THE MAJOR MECHANISM CAUSING DIC. The largest functional group studied comprised genes related to ROS production. H₂O₂ production analysis in cardiomyocytes exposed to doxorubicin revealed reduced production in *CBR1*-KO and *CBR3*-KO hiPSC-CMs, indicating a potential link to cardiotoxicity via reduced metabolism of doxorubicin to doxorubicinol by carbonyl reductases. In contrast, *HAS3*-KO, *SPG7*-KO, *GSTM1*-KO, and *RAC2*-KO exhibited higher ROS production and increased sensitivity to doxorubicin, indicating a role of these genes in H₂O₂ handling. Notably, no significant differences in H₂O₂ production were observed in *CAT*-KO, *NOS3*-KO, *PLCE1*-KO, *GPX3*-KO, *ERBB2*-KO, and *GSTP1*-KO. This might suggest that the DIC observed in the KO of these genes is due to the defects in the handling and detoxification of additional ROS products and/or participation in other mechanisms related to doxorubicin toxicity besides ROS generation. In fact, it has been shown that *CAT*, glutathione S-transferases, and glutathione peroxidases have played crucial roles in detoxifying metabolites generated during oxidative stress.⁶¹

DNA DAMAGE RESPONSE IS ELEVATED IN *PRDM2*-KO AND *MHL1*-KO. *RARG* inhibits *TOP2B*, which binds to DNA and stabilizes the intermediate *TOP2B*-mediated double-stranded DNA breaks. KOs of the *RARG* gene activate this DNA damage pathway, leading to increased cardiac cell death. Similar mechanisms are thought to exist in *PRDM2* and *MLH1* gene KOs. We detected higher levels of DNA damage after doxorubicin treatments *PRDM2*-KO and *MHL1*-KO, suggesting a protective role for these genes against doxorubicin-induced DNA damage.

***HFE*-KO CARDIOMYOCYTES EXHIBIT REDUCED IRON UPTAKE.** Our results indicate reduced iron uptake in *HFE*-KO cardiomyocytes compared with isogenic control, particularly evident at high Fe²⁺ concentrations (100 μM). Considering the important role of iron in mitochondrial function and the energy-demanding nature of cardiomyocytes, this impaired iron uptake may contribute to the heightened DIC observed in

HFE-KO cardiomyocytes, as evidenced by the exacerbated risk for heart failure in the context of iron deficiency.⁶²

KOs OF SLC TRANSPORTERS REDUCE AND ABC TRANSPORTERS KOs INCREASE THE DOXORUBICIN UPTAKE. KOs of SLC family members in hiPSC-CMs showed reduced doxorubicin uptake compared with isogenic controls. In addition, KO of ABC family members in hiPSC-CMs resulted in an elevation of doxorubicin uptake. Our results indicate that SLC transporters play a crucial role in facilitating the influx of doxorubicin into the cardiomyocytes, thereby contributing to an increased risk for DIC. Conversely, ABC transporters are implicated in the efflux of doxorubicin out of the cells, reducing intracellular doxorubicin levels and establishing them as potential cardioprotective gene targets.

***CELF4*-KO AND *MYH7*-KO hiPSC-CMs DEMONSTRATE ALTERED CALCIUM TRANSIENTS.** *CELF4* is involved in regulatory splicing events essential for the proper functioning of cardiac troponin T, which in turn plays an essential role in proper calcium signaling in cardiomyocytes.⁶³ *MYH7*, a gene encoding myosin heavy chain beta isoform, is associated with increased intracellular calcium levels in patients with hypertrophic cardiomyopathy.⁶⁴ Our analysis revealed alterations in multiple aspects of calcium transients in both *CELF4*-KO and *MYH7*-KO, suggesting impaired calcium handling as one of the mechanisms underlying DIC.

CONTRACTILE PROPERTIES OF *ZFN521*-KO, *RIN3*-KO, AND *CYP2J2*-KO hiPSC-CMs ARE AFFECTED. *ZFN521* regulates the ventricular conduction system in the heart,⁶⁵ while *RIN3* interacts with and regulates *RAB5*, facilitating membrane trafficking of the voltage-gated potassium channel *KCNQ1* and thereby regulating potassium currents.⁶⁶ *CYP2J2* KO has been shown to result in QT-interval prolongation on echocardiography.⁶⁷ Impedance analysis of *ZFN521*-KO, *RIN3*-KO, and *CYP2J2*-KO hiPSC-CMs revealed significant differences in contractile properties, including beat rate, pulse width at 50%, upstroke velocity, and relaxation velocity, compared with the isogenic control.

STUDY LIMITATIONS. Although we investigated the KO of gene candidates from GWAS and candidate gene association studies, these studies identified SNPs linked to AIC. Because not all the SNPs cause loss of function, studying individual SNP corrections and/or patient-specific hiPSC-CMs can shed further light on this matter. Additionally, we generated KOs of selected candidate genes on the basis of their potential link to AIC and expression in hiPSC-CMs. Although not all the generated KOs showed

significant differences in LD₅₀ after doxorubicin treatment, repeating this process using KO of a gene with no proven function in AIC could further validate these findings. Additionally, the application of more mature cardiomyocytes could assist to harness the differences in a more physiologically relevant system. The present study was focused only on the effect of KOs on cardiomyocytes, but cardiotoxicity might stem from malfunction in other cell types, including endothelial cells and cardiac fibroblasts. Finally, for each KO, only 1 functional study was performed; additional functional studies can provide a more detailed understanding of each gene contribution to the formation of DIC.

CONCLUSIONS

This study demonstrates that genomic analysis, coupled with human induced pluripotent stem cell modeling, is an efficient platform for assessing the mechanisms of DIC. Through high-throughput assays, we validate the influence of DIC genes on cell viability, ROS production, DNA damage, doxorubicin uptake, iron uptake, calcium handling, and electric activity in response to doxorubicin. Our results confirm that more than 55% of the DIC genes identified to date in association studies are expressed in cardiac cells, reliably recapitulating alterations in DIC phenotype in the hiPSC-CM model. Furthermore, for each gene, we provide a functional assay to validate its role in DIC.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

This work was supported by National Institutes of Health grants R01 CA220002 and R01 CA261898, American Heart Association Transformatonal Project Award 18TPA34230105, and the Leducq Foundation (to Dr Burrige). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Paul W. Burrige, Northwestern University Feinberg School of Medicine, 320 East Superior Street, Searle 8-525, Chicago, Illinois 60611, USA. E-mail: paul.burrige@northwestern.edu. @pwburrige.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: In this study, we have functionally validated all current DIC-associated genes that are expressed in cardiomyocytes. This comprehensive validation represents the first step in translating functionally validated genotype-phenotype correlations into clinical tests. Once the relevance of a gene in DIC is identified, and its mechanism of action is known, the next step involves validating the role of genetic variants in modulating the response to doxorubicin. This information will serve as a unique platform for designing polygenic risk scores that can benefit patients undergoing doxorubicin treatment. In addition, a precise understanding of the genetic basis of DIC is crucial for identifying druggable targets and discovering innovative cardioprotective therapies.

TRANSLATIONAL OUTLOOK: One major barrier in the clinical application of this study lies in determining the genetic contribution to DIC risk for each gene for all sexes and ancestries. Currently, there is a scarcity of studies exploring the effects of sex and diverse genetic backgrounds on the mechanisms of DIC. Establishing patient-specific risk factors is a crucial prerequisite before the clinical implementation of the findings from this study can be applied.

REFERENCES

- Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. *JACC: CardioOncology* state-of-the-art review. *J Am Coll Cardiol CardioOnc*. 2020;2(4):539-552. <https://doi.org/10.1016/j.jacc.2020.09.006>
- Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015;131(22):1981-1988. <https://doi.org/10.1161/CIRCULATIONAHA.114.013777>
- Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. *Nat Genet*. 2015;47(9):1079-1084. <https://doi.org/10.1038/ng.3374>
- Schneider BP, Shen F, Gardner L, et al. Genome-wide association study for anthracycline-induced congestive heart failure. *Clin Cancer Res*. 2017;23(1):43-51. <https://doi.org/10.1158/1078-0432.CCR-16-0908>
- Wells QS, Veatch OJ, Fessel JP, et al. Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. *Pharmacogenet Genomics*. 2017;27(7):247-254. <https://doi.org/10.1097/FPC.0000000000000284>
- Wang X, Sun CL, Quinones-Lombrana A, et al. CELF4 variant and anthracycline-related cardiomyopathy: a Children's Oncology Group genome-wide association study. *J Clin Oncol*. 2016;34(8):863-870. <https://doi.org/10.1200/JCO.2015.63.4550>

7. Park B, Sim SH, Lee KS, Kim HJ, Park IH. Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer. *Cancer Sci*. 2020;111(7):2579-2587. <https://doi.org/10.1111/cas.14446>
8. Magdy T, Burridge PW. Use of hiPSC to explore genomic predisposition to anthracycline-induced cardiotoxicity. *Pharmacogenomics*. 2021;22(1):41-54. <https://doi.org/10.2217/pgs-2020-0104>
9. Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. *J Clin Oncol*. 2012;30(13):1422-1428. <https://doi.org/10.1200/JCO.2010.34.3467>
10. Visscher H, Ross CJ, Rassekh SR, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. *Pediatr Blood Cancer*. 2013;60(8):1375-1381. <https://doi.org/10.1002/pbc.24505>
11. Minotti G, Recalcati S, Mordente A, et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. *FASEB J*. 1998;12(7):541-552. <https://doi.org/10.1096/fasebj.12.7.541>
12. Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. *Pharmacogenomics*. 2015;16(10):1065-1076. <https://doi.org/10.2217/pgs.15.61>
13. Magdy T, Jouni M, Kuo HH, et al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. *Circulation*. 2022;145(4):279-294. <https://doi.org/10.1161/CIRCULATIONAHA.121.055801>
14. Krajcinovic M, Elbared J, Drouin S, et al. Polymorphisms of ABCB5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. *Pharmacogenomics J*. 2016;16(6):530-535. <https://doi.org/10.1038/tpj.2015.63>
15. Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. *Life Sci*. 2002;70(20):2377-2389. [https://doi.org/10.1016/S0024-3205\(02\)01524-2](https://doi.org/10.1016/S0024-3205(02)01524-2)
16. Keung EC, Toll L, Ellis M, Jensen RA. L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations. *J Clin Invest*. 1991;87(6):2108-2113. <https://doi.org/10.1172/JCI115241>
17. Benjanuwattara J, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies. *Pharmacol Res*. 2020;151:104542. <https://doi.org/10.1016/j.phrs.2019.104542>
18. Burridge PW, Li YF, Matsa E, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. *Nat Med*. 2016;22(5):547-556. <https://doi.org/10.1038/nm.4087>
19. Magdy T, Jiang Z, Jouni M, et al. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. *Cell Stem Cell*. 2021;28(12):2076-2089.e7. <https://doi.org/10.1016/j.stem.2021.08.006>
20. Singh P, Wang X, Hageman L, et al. Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer—a Children's Oncology Group ALTEO3N1 report. *Cancer*. 2020;126(17):4051-4058. <https://doi.org/10.1002/cncr.32948>
21. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group. *J Clin Oncol*. 2012;30(13):1415-1421. <https://doi.org/10.1200/JCO.2011.34.8987>
22. Gabrielson K, Bedja D, Pin S, et al. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. *Cancer Res*. 2007;67(4):1436-1441. <https://doi.org/10.1158/0008-5472.CAN-06-3721>
23. El-Tokhy MA, Hussein NA, Bedewy AML, Barakat MR. XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients. *Hematology*. 2014;19(7):397-403. <https://doi.org/10.1179/1607845413Y.0000000144>
24. Semsei AF, Erdelyi DJ, Ungvari I, et al. ABCB1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. *Cell Biol Int*. 2012;36(1):79-86. <https://doi.org/10.1042/CBI20110264>
25. Hertz DL, Caram MV, Kidwell KM, et al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. *Pharmacogenomics*. 2016;17(3):231-240. <https://doi.org/10.2217/pgs.15.162>
26. Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. *Nat Rev Clin Oncol*. 2013;10(12):697-710. <https://doi.org/10.1038/nrclinonc.2013.195>
27. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. *Cancer*. 2012;118(7):1856-1867. <https://doi.org/10.1002/cncr.26472>
28. Leger KJ, Cushing-Haugen K, Hansen JA, et al. Clinical and genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors. *Biol Blood Marrow Transplant*. 2016;22(6):1094-1101. <https://doi.org/10.1016/j.bbmt.2016.02.017>
29. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation*. 2005;112(24):3754-3762. <https://doi.org/10.1161/CIRCULATIONAHA.105.576850>
30. Lubieniecka JM, Liu J, Graham J, et al. Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction. *Cancer Epidemiol Biomarkers Prev*. 2013;22(10):1918-1920. <https://doi.org/10.1158/1055-9965.EPI-13-0671>
31. Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. *Leuk Lymphoma*. 2009;50(10):1693-1698. <https://doi.org/10.1080/10428190903177212>
32. Kang YJ, Sun X, Chen Y, Zhou Z. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. *Chem Res Toxicol*. 2002;15(1):1-6. <https://doi.org/10.1021/tx015532n>
33. Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. *Br J Haematol*. 2013;163(2):205-213. <https://doi.org/10.1111/bjh.12516>
34. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. *Annu Rev Pharmacol Toxicol*. 2007;47:293-322. <https://doi.org/10.1146/annurev.pharmtox.47.120505.105316>
35. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. *JAMA Oncol*. 2016;2(8):1030-1037. <https://doi.org/10.1001/jamaoncol.2016.1726>
36. Belmonte F, Das S, Sysa-Shah P, et al. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. *Am J Physiol Heart Circ Physiol*. 2015;309(8):H1271-H1280. <https://doi.org/10.1152/ajpheart.00517.2014>
37. Doroshov JH, Esworthy RS, Chu FF. Control of doxorubicin-induced, reactive oxygen-related apoptosis by glutathione peroxidase 1 in cardiac fibroblasts. *Biochem Biophys Res*. 2020;21:100709. <https://doi.org/10.1016/j.bbrep.2019.100709>
38. Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. *Leukemia*. 2009;23(6):1118-1126. <https://doi.org/10.1038/leu.2008.398>
39. Yin Z, Ivanov VN, Habelhah H, Tew K, Ronai Z. Glutathione S-transferase p elicits protection against H₂O₂-induced cell death via coordinated regulation of stress kinases. *Cancer Res*. 2000;60(15):4053-4057.
40. Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. *J Clin Oncol*. 2014;32(7):647-653. <https://doi.org/10.1200/JCO.2013.50.3557>
41. Law CH, Li JM, Chou HC, Chen YH, Chan HL. Hyaluronic acid-dependent protection in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment. *Toxicology*. 2013;303:54-71. <https://doi.org/10.1016/j.tox.2012.11.006>

42. Neilan TG, Blake SL, Ichinose F, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. *Circulation*. 2007;116(5):506-514. <https://doi.org/10.1161/CIRCULATIONAHA.106.652339>
43. Hildebrandt MAT, Reyes M, Wu X, et al. Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors. *Sci Rep*. 2017;7(1):9698. <https://doi.org/10.1038/s41598-017-09517-2>
44. Tripaydonis A, Conyers R, Elliott DA. Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling. *Clin Pharmacol Ther*. 2019;105(3):614-624. <https://doi.org/10.1002/cpt.1311>
45. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. *Circ Res*. 2006;98(4):453-462. <https://doi.org/10.1161/01.RES.0000204727.46710.5e>
46. Almontashiri NA, Chen HH, Mailloux RJ, et al. SPG7 variant escapes phosphorylation-regulated processing by AFG3L2, elevates mitochondrial ROS, and is associated with multiple clinical phenotypes. *Cell Rep*. 2014;7(3):834-847. <https://doi.org/10.1016/j.celrep.2014.03.051>
47. Cho C, Jung-Ha H, Willis WD, et al. Protamine 2 deficiency leads to sperm DNA damage and embryo death in mice. *Biol Reprod*. 2003;69(1):211-217. <https://doi.org/10.1095/biolreprod.102.015115>
48. Romeo F, Falbo L, Di Sanzo M, et al. BRCA1 is required for hMLH1 stabilization following doxorubicin-induced DNA damage. *Int J Biochem Cell Biol*. 2011;43(12):1754-1763. <https://doi.org/10.1016/j.biocel.2011.08.011>
49. Miranda CJ, Makui H, Soares RJ, et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. *Blood*. 2003;102(7):2574-2580. <https://doi.org/10.1182/blood-2003-03-0869>
50. Andreev E, Brosseau N, Carmona E, Mes-Masson AM, Ramotar D. The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. *Sci Rep*. 2016;6:20508. <https://doi.org/10.1038/srep20508>
51. Smith AJ, van Helvoort A, van Meer G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. *J Biol Chem*. 2000;275(31):23530-23539. <https://doi.org/10.1074/jbc.M909002199>
52. Lian G, Yuan J, Gao Y. In vitro transport ability of ABC2 (G1249A) polymorphic variant towards anticancer drugs. *Onco Targets Ther*. 2020;13:1413-1419. <https://doi.org/10.2147/OTT.S207613>
53. Wang JQ, Wu ZX, Yang Y, et al. ATP-binding cassette (ABC) transporters in cancer: a review of recent updates. *J Evid Based Med*. Sep. 2021;14(3):232-256. <https://doi.org/10.1111/jebm.12434>
54. Ladd AN, Stenberg MG, Swanson MS, Cooper TA. Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development. *Dev Dyn*. 2005;233(3):783-793. <https://doi.org/10.1002/dvdy.20382>
55. Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, et al. Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. *Open Heart*. 2014;1(1):e000116. <https://doi.org/10.1136/openhrt-2014-000116>
56. Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. *Cell Stem Cell*. 2013;12(1):101-113. <https://doi.org/10.1016/j.stem.2012.10.010>
57. Arnold WR, Baylon JL, Tajkhorshid E, Das A. Arachidonic acid metabolism by human cardiovascular CYP2J2 is modulated by doxorubicin. *Biochemistry*. 2017;56(51):6700-6712. <https://doi.org/10.1021/acs.biochem.7b01025>
58. Seeböhm G, Strutz-Seeböhm N, Birkin R, et al. Regulation of endocytic recycling of KCNQ1/KCNE1 potassium channels. *Circ Res*. 2007;100(5):686-692. <https://doi.org/10.1161/01.RES.0000260250.83824.8f>
59. Singh A, Babyak MA, Nolan DK, et al. Gene by stress genome-wide interaction analysis and path analysis identify EBF1 as a cardiovascular and metabolic risk gene. *Eur J Hum Genet*. 2015;23(6):854-862. <https://doi.org/10.1038/ejhg.2014.189>
60. Wu Q, Vasquez KM. Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand cross-links, while MSH2 functions in DNA repair. *PLoS Genet*. 2008;4(9):e1000189. <https://doi.org/10.1371/journal.pgen.1000189>
61. Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. *Oncogenesis*. 2018;7(1):8. <https://doi.org/10.1038/s41389-017-0025-3>
62. Zhang H, Zhabeyev P, Wang S, Oudit GY. Role of iron metabolism in heart failure: From iron deficiency to iron overload. *Biochim Biophys Acta Mol Basis Dis*. 2019;1865(7):1925-1937. <https://doi.org/10.1016/j.bbadis.2018.08.030>
63. Biesiadecki BJ, Elder BD, Yu ZB, Jin JP. Cardiac troponin T variants produced by aberrant splicing of multiple exons in animals with high instances of dilated cardiomyopathy. *J Biol Chem*. 2002;277(52):50275-50285. <https://doi.org/10.1074/jbc.M206369200>
64. Dainis A, Zaleta-Rivera K, Ribeiro A, et al. Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. *Physiol Genom*. 2020;52(7):293-303. <https://doi.org/10.1152/physiolgenomics.00021.2020>
65. Litvinukova M, Talavera-Lopez C, Maatz H, et al. Cells of the adult human heart. *Nature*. 2020;588(7838):466-472. <https://doi.org/10.1038/s41586-020-2797-4>
66. Kajihō H, Sakurai K, Minoda T, et al. Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31. *J Biol Chem*. 2011;286(27):24364-24373. <https://doi.org/10.1074/jbc.M110.172445>
67. Solanki M, Pointon A, Jones B, Herbert K. Cytochrome P450 2J2: potential role in drug metabolism and cardiotoxicity. *Drug Metab Dispos*. 2018;46(8):1053-1065. <https://doi.org/10.1124/dmd.117.078964>

KEY WORDS cardiomyocytes, doxorubicin, genomics, GWAS, human induced pluripotent stem cells

APPENDIX For supplemental methods, tables, and figures, please see the online version of this paper.